In Vitro Activities of Anidulafungin and Other Antifungal Agents against Biofilms Formed by Clinical Isolates of Different Candida and Aspergillus Species

ABSTRACT We tested the activities of anidulafungin and other antifungal agents against clinical isolates of different fungal species. For Candida species, high sessile MIC90s (SMIC90s) were obtained for fluconazole, voriconazole, and amphotericin B, whereas the anidulafungin SMIC90s were very low, as were those for caspofungin. Comparatively, for Aspergillus species, higher SMIC90 values were obtained not only for amphotericin B and voriconazole but also for the echinocandins.

[1]  A. Beauvais,et al.  Aspergillus fumigatus biofilms in the clinical setting. , 2011, Medical mycology.

[2]  C. Munro,et al.  Fungal echinocandin resistance , 2010, F1000 biology reports.

[3]  H. Sanchez,et al.  Genetic basis of Candida biofilm resistance due to drug-sequestering matrix glucan. , 2010, The Journal of infectious diseases.

[4]  Ronald N. Jones,et al.  Potency of Anidulafungin Compared to Nine Other Antifungal Agents Tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: Results from the Global SENTRY Antimicrobial Surveillance Program (2008) , 2010, Journal of Clinical Microbiology.

[5]  F. Müller,et al.  Liposomal amphotericin B eradicates Candida albicans biofilm in a continuous catheter flow model. , 2010, FEMS yeast research.

[6]  C. d’Enfert,et al.  Interaction of Candida albicans Biofilms with Antifungals: Transcriptional Response and Binding of Antifungals to Beta-Glucans , 2010, Antimicrobial Agents and Chemotherapy.

[7]  A. Beauvais,et al.  In vivo biofilm composition of Aspergillus fumigatus , 2010, Cellular microbiology.

[8]  J. Lopez-Ribot,et al.  Our Current Understanding of Fungal Biofilms , 2009, Critical reviews in microbiology.

[9]  N. Jain,et al.  Biofilm formation in clinical Candida isolates and its association with virulence. , 2009, Microbes and infection.

[10]  Craig Williams,et al.  Phase-dependent antifungal activity against Aspergillus fumigatus developing multicellular filamentous biofilms. , 2008, The Journal of antimicrobial chemotherapy.

[11]  F. Müller,et al.  Aspergillus fumigatus Forms Biofilms with Reduced Antifungal Drug Susceptibility on Bronchial Epithelial Cells , 2008, Antimicrobial Agents and Chemotherapy.

[12]  J. Lopez-Ribot,et al.  A simple and reproducible 96-well plate-based method for the formation of fungal biofilms and its application to antifungal susceptibility testing , 2008, Nature Protocols.

[13]  Robin Patel,et al.  In Vitro Activity of Anidulafungin against Candida albicans Biofilms , 2008, Antimicrobial Agents and Chemotherapy.

[14]  A. Stringaro,et al.  Increase of Virulence and Its Phenotypic Traits in Drug-Resistant Strains of Candida albicans , 2008, Antimicrobial Agents and Chemotherapy.

[15]  E. Diza-Mataftsi,et al.  Differential Activities of Newer Antifungal Agents against Candida albicans and Candida parapsilosis Biofilms , 2007, Antimicrobial Agents and Chemotherapy.

[16]  Craig Williams,et al.  Development of a simple model for studying the effects of antifungal agents on multicellular communities of Aspergillus fumigatus. , 2007, Journal of medical microbiology.

[17]  D. Perlin.  Resistance to echinocandin-class antifungal drugs. , 2007, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[18]  A. Beauvais,et al.  An extracellular matrix glues together the aerial‐grown hyphae of Aspergillus fumigatus , 2007, Cellular microbiology.

[19]  G. Fadda,et al.  Biofilm Production by Candida Species and Inadequate Antifungal Therapy as Predictors of Mortality for Patients with Candidemia , 2007, Journal of Clinical Microbiology.

[20]  D. Perlin,et al.  Serum Differentially Alters the Antifungal Properties of Echinocandin Drugs , 2007, Antimicrobial Agents and Chemotherapy.

[21]  Robin Patel,et al.  In vitro biofilm characterization and activity of antifungal agents alone and in combination against sessile and planktonic clinical Candida albicans isolates. , 2007, Diagnostic microbiology and infectious disease.

[22]  S. Suh,et al.  Species-Specific Differences in the Susceptibilities of Biofilms Formed by Candida Bloodstream Isolates to Echinocandin Antifungals , 2007, Antimicrobial Agents and Chemotherapy.

[23]  L. J. Douglas,et al.  Penetration of Candida Biofilms by Antifungal Agents , 2004, Antimicrobial Agents and Chemotherapy.

[24]  M. Ghannoum,et al.  Antifungal Susceptibility of Candida Biofilms: Unique Efficacy of Amphotericin B Lipid Formulations and Echinocandins , 2002, Antimicrobial Agents and Chemotherapy.

[25]  M. Ghannoum,et al.  Comparison of Biofilms Formed by Candidaalbicans and Candidaparapsilosis on Bioprosthetic Surfaces , 2002, Infection and Immunity.

[26]  Li Guanghu,et al.  Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection:2009 update by the Infectious Diseases Society of America , 2010 .

[27]  Clinical,et al.  Reference method for broth dilution antifungal susceptibility testing of filamentous fungi : Approved standard , 2008 .

[28]  Clinical,et al.  Reference method for broth dilution antifungal susceptibility testing of yeasts : Approved standard , 2008 .